Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Biochemicals » Biochem-Inhibitors » Dasatinib (N-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, BMS-354825)

yl]amino]-5-thiazolecarboxamide, BMS-354825)


  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.


Dasatinib, also known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinases inhibitor approved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is also being assessed for use in metastatic melanoma.
Catalog #D1079
Related Substances (HPLC)Any single impurity:
Total Impurities:
SolubilityInsoluble in water and slightly soluble in ethanol and methanol
Method for Determining IdentityProton NMR Spectroscopic Analysis, HPLC
Loss on Drying 0.5%
Residue on ignition 0.2%
Heavy Metals 0.002%
CAS Number302962-49-8
Molecular FormulaC22H26ClN7O2S
Molecular Weight488.1
FormSupplied as an off-white to pale yellow powder
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Alternate namesN-[2-Chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide

External Links